- Home
- REFI vs ACIU Comparison
REFI vs ACIU Comparison
Compare REFI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- ACIU
- Stock Information
- Founded
- REFI 2021
- ACIU 2003
- Country
- REFI United States
- ACIU Switzerland
- Employees
- REFI N/A
- ACIU N/A
- Industry
- REFI Real Estate Investment Trusts
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- ACIU Health Care
- Exchange
- REFI Nasdaq
- ACIU Nasdaq
- Market Cap
- REFI 306.1M
- ACIU 332.4M
- IPO Year
- REFI 2021
- ACIU 2016
- Fundamental
- Price
- REFI $16.21
- ACIU $2.71
- Analyst Decision
- REFI Strong Buy
- ACIU Strong Buy
- Analyst Count
- REFI 3
- ACIU 2
- Target Price
- REFI $20.00
- ACIU $12.00
- AVG Volume (30 Days)
- REFI 121.4K
- ACIU 130.0K
- Earning Date
- REFI 11-07-2024
- ACIU 11-05-2024
- Dividend Yield
- REFI 11.60%
- ACIU N/A
- EPS Growth
- REFI N/A
- ACIU N/A
- EPS
- REFI 2.00
- ACIU N/A
- Revenue
- REFI $56,860,278.00
- ACIU $48,505,404.00
- Revenue This Year
- REFI N/A
- ACIU $85.33
- Revenue Next Year
- REFI $4.27
- ACIU $80.69
- P/E Ratio
- REFI $8.11
- ACIU N/A
- Revenue Growth
- REFI 6.49
- ACIU 4097200.00
- 52 Week Low
- REFI $14.82
- ACIU $2.25
- 52 Week High
- REFI $16.75
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- REFI 58.66
- ACIU 29.89
- Support Level
- REFI $15.69
- ACIU $2.62
- Resistance Level
- REFI $16.24
- ACIU $3.07
- Average True Range (ATR)
- REFI 0.20
- ACIU 0.15
- MACD
- REFI -0.02
- ACIU -0.04
- Stochastic Oscillator
- REFI 90.32
- ACIU 17.24
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.